EUVIMEDEUVIMED entdecken
Crossref

tRF-Gly-CCC-012 enhances malignant process in pancreatic cancer via the HNRNPC/PHGDH axis

Xiaohong Li, Yue Pan, Luolin Zhou, Lei Qi, Jingjing Lu

Biochemical Pharmacology · 2026

DOI: 10.1016/j.bcp.2026.117726 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Xiaohong Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China; School of Pharmacy, Nantong University, Nanto…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Heterogeneous-Nuclear Ribonucleoprotein Group C, RNA, Transfer. Die Arbeit nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer (PC) is a devastating disease with rising incidence and mortality rates, characterized by late-stage presentation and aggressive progression, underscoring the urgent need for effective therapies. Recent studies have highlighted tRNA-derived fragments (tRFs) as potential therapeutic targets and biomarkers in cancer. In this study, we identified the cancer-associated tRF, tRF-Gly-CCC-012, which was observed to be highly expressed in PC tissues and cell lines. FISH and Nuclear/cytoplasmic RNA isolation analyses showed that tRF-Gly-CCC-012 was predominantly localized in the cytoplasm. Knockdown of tRF-Gly-CCC-012 suppressed aggressive phenotypes in PC cells, whereas its overexpression conversely promoted malignancy in PC organoids. In vivo experiments further confirmed that inhibition of tRF-Gly-CCC-012 suppressed PC cell growth. Mechanistically, RNA sequencing analysis demonstrated that tRF-Gly-CCC-012 upregulated the expression of PHGDH, involved in serine synthesis. RNA pulldown assays combined with mass spectrometry (MS) showed that tRF-Gly-CCC-012 specifically bound to the 162-306 amino acid domain of HNRNPC. Furthermore, tRF-Gly-CCC-012 enhanced HNRNPC protein expression by inhibiting its ubiquitination and degradation, leading to an upregulation of PHGDH and promoting the malignant progression of PC. These findings highlight tRF-Gly-CCC-012 as a viable diagnostic biomarker for PC, providing insights for detection and innovative strategies for clinical intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsHeterogeneous-Nuclear Ribonucleoprotein Group CRNA, TransferHumansAnimalsCell Line, TumorMice, NudeMice

Stichwörter der Autor:innen

HNRNPCMalignant phenotypePHGDHPancreatic cancertRF-Gly-CCC-012

Substanzen

Heterogeneous-Nuclear Ribonucleoprotein Group CHNRNPC protein, humanRNA, Transfer

Autor:innen und Institutionen

  • Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China; School of Pharmacy, Nantong University, Nantong 226000, China.
  • Medical College, Nantong University, Nantong 226000, China.
  • School of Pharmacy, Nantong University, Nantong 226000, China. Electronic address: ql@ntu.edu.cn.
  • Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China. Electronic address: lujingjing1986@126.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, X., Pan, Y., Zhou, L., Qi, L., & Lu, J. (2026). tRF-Gly-CCC-012 enhances malignant process in pancreatic cancer via the HNRNPC/PHGDH axis. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.117726

Vancouver

Li X, Pan Y, Zhou L, Qi L, Lu J. tRF-Gly-CCC-012 enhances malignant process in pancreatic cancer via the HNRNPC/PHGDH axis. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.117726

BibTeX
@article{Li2026,
  author = {Li, Xiaohong and Pan, Yue and Zhou, Luolin and Qi, Lei and Lu, Jingjing},
  title = {tRF-Gly-CCC-012 enhances malignant process in pancreatic cancer via the HNRNPC/PHGDH axis},
  journal = {Biochemical Pharmacology},
  year = {2026},
  doi = {10.1016/j.bcp.2026.117726}
}
Kostenlos starten →